Navigation Links
Repligen Announces Long Term Supply Agreement with GE Healthcare for Recombinant Protein A
Date:1/28/2010

WALTHAM, Mass., Jan. 28 /PRNewswire-FirstCall/ -- Repligen Corporation (Nasdaq: RGEN) announced today that it has extended its longstanding relationship with GE Healthcare Bio-Sciences AB by entering into a five-year supply agreement for recombinant Protein A, a consumable used in the manufacture of monoclonal antibodies, a highly successful class of biopharmaceutical.  Repligen is the world's leading supplier of recombinant Protein A and has manufactured recombinant Protein A for GE Healthcare for more than 10 years.  This agreement provides for Repligen to continue to be a strategic supplier to GE Healthcare through 2014.  GE Healthcare sells chromatography products which incorporate Repligen's recombinant Protein A to the biopharmaceutical industry for the manufacture of monoclonal antibodies.

"We are very pleased to continue our long standing relationship with GE Healthcare," stated Walter C. Herlihy, President and Chief Executive Officer of Repligen Corporation.  "This agreement ensures continuity in the supply of high quality recombinant Protein A supported by our business continuity plans and quality systems that are required by the biopharmaceutical industry."

There are currently more than 25 monoclonal antibodies that have received regulatory approval with more than 200 products in various stages of clinical development.  The worldwide revenues from this class of drug exceeded $35 billion in 2009.

About Repligen Corporation

Repligen Corporation is a biopharmaceutical company focused on the development of novel therapeutics for neurological disorders.  In addition, we are the world's leading supplier of recombinant Prote
'/>"/>

SOURCE Repligen Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Repligen Reports Positive Phase 2a Clinical Trial Results of RG2417 for Symptoms of Bipolar Disorder
2. Repligen Initiates Phase 3 Clinical Trial of RG1068 for Pancreatic MRI Imaging
3. Repligen Receives FDA Fast Track Designation for RG1068 for Pancreatic Imaging
4. Repligen Announces Plans to Initiate a Phase 2b Trial for RG2417 in Bipolar Disorder
5. Repligen Reports Phase 3 Clinical Trial Results of RG1068 in Pancreatic Imaging
6. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
7. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
8. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
9. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
10. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
11. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... , Dec. 24, 2014  Novastem, a ... its first patient in its study for ischemic ... American Stroke Association, ischemic strokes account for 87 ... enroll qualified patients in the study, entitled "Internal ... of Allogeneic Mesenchymal Stem Cells and Intrathecal Administration ...
(Date:12/24/2014)... HARRISBURG, Pa. , Dec. 24, 2014  Commonwealth Cornerstone ... New Markets Tax Credits transaction on Tuesday to help fund ... Health Network (PHN) in Sharon . ... operating in Pennsylvania . It is the ... district, with more than 150 people on staff. ...
(Date:12/24/2014)... 2014 Kinex Pharmaceuticals announced today that the ... Park Cancer Institute. KX2-361 (KX02), a dual ... shown potent inhibitory activity against a broad panel of ... to Temozolomide (T98G), the most widely used chemotherapy for ... tumor mouse model, KX2-361 consistently clears brain tumors after ...
Breaking Medicine Technology:Novastem Treats First Patient Using Stemedica's Mesenchymal and Neural Stem Cell Combination Therapy for Ischemic Stroke 2Novastem Treats First Patient Using Stemedica's Mesenchymal and Neural Stem Cell Combination Therapy for Ischemic Stroke 3Novastem Treats First Patient Using Stemedica's Mesenchymal and Neural Stem Cell Combination Therapy for Ischemic Stroke 4Commonwealth Cornerstone Group Announces $8 Million in Tax Credits to Expand and Consolidate Healthcare Services in Sharon 2Commonwealth Cornerstone Group Announces $8 Million in Tax Credits to Expand and Consolidate Healthcare Services in Sharon 3Kinex Pharmaceuticals Announces First Patient Dosed with KX2-361 in a Phase 1 Clinical Study 2Kinex Pharmaceuticals Announces First Patient Dosed with KX2-361 in a Phase 1 Clinical Study 3
... 2011 For the second year in a row Royce ... Associates, received a supplier recognition from Carestream Health, the world,s ... Carestream Health, which supplies a complete line of Medical and ... Royce their 2010 Supplier of the Year , Carestream,s ...
... 2011 Transgenomic, Inc. (OTC/BB: TBIO) today reported financial results for ... update. First Quarter Financial Results ... $7.5 million, an increase of 37 percent compared with $5.4 million ... or 56 percent of net sales, compared with gross profit of ...
Cached Medicine Technology:Royce Receives Coveted Medical Products Award 2Transgenomic Reports First Quarter Financial Results 2Transgenomic Reports First Quarter Financial Results 3Transgenomic Reports First Quarter Financial Results 4Transgenomic Reports First Quarter Financial Results 5Transgenomic Reports First Quarter Financial Results 6Transgenomic Reports First Quarter Financial Results 7Transgenomic Reports First Quarter Financial Results 8Transgenomic Reports First Quarter Financial Results 9
(Date:12/26/2014)... (PRWEB) December 26, 2014 India Network ... insurance in the USA, announced today a new version ... members in choosing the right plan for their visiting ... complexity out of the selection process when choosing an ... age group with only a few clicks. Many elderly ...
(Date:12/25/2014)... 26, 2014 The microscopy market ... 7.2% to reach $5,756.0 million by 2019. Optical ... market. The electron microscopes product segment is expected ... period. , Rising focus on nanotechnology, technological advancements, ... the microscopy market. , Get Full Copy of ...
(Date:12/25/2014)... Dallas, TX (PRWEB) December 26, 2014 ... Analysis to 2023” focuses on the current treatment landscape, ... colorectal cancer market. TS-1 is an anti-cancer drug which ... administered orally and is also used for treating gastric ... gimestat and otastat potassium. The drug was first approved ...
(Date:12/25/2014)... 26, 2014 Recently, Dylan Queen, a ... excitedly released its collection of discounted prom dresses, most ... a senior spokesman of the company, the promotion is ... promotion is to expand the UK market. , The ... different colors, lengths, and styles: A-line strapless, empire strapless ...
(Date:12/25/2014)... Helen Harris’ RP (Retinitis Pigmentosa) International founder ... an 8 year battle with breast cancer. , ... her home in Woodland Hills California after an 8 ... , As the founder and volunteer President of ... championed many of today's greatest breakthroughs in restoring and ...
Breaking Medicine News(10 mins):Health News:India Network Health Insurance Announces new Comprehensive Pre-existing Condition Coverage policy for Visitors to the United States 2Health News:India Network Health Insurance Announces new Comprehensive Pre-existing Condition Coverage policy for Visitors to the United States 3Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 2Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 3Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 4Health News:TS-1 Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:TS-1 Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:Dylan Queen: Cheap Prom Dresses for the UK Market 2Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 2Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 3Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 4
... report not feeling impaired, researchers say, , , THURSDAY, March 5 ... have noted that you can,t handle that third glass of ... confirms it,s not their imagination. , Older adults who are ... or two drinks and not realize it, University of Kentucky ...
... (March 3, 2009) - How messages sent within stem cells ... specialize and become blood cells in humans, has been discovered ... Institute. , The finding, to be published in the March ... first time scientists have demonstrated the importance of the pathway, ...
... viruses that have emerged in recent outbreaks are susceptible to ... according to a new basic science study by researchers at ... . Due to the study,s significance, a manuscript was published ... highlighted as an,editor,s "spotlight" in the first May issue. , ...
... 5 SCOLR Pharma, Inc. (NYSE Alternext US: DDD) today ... Wednesday, March 11, 2009, at 8:30 a.m. Eastern. Dr. Bruce ... the conference call at 11:30 a.m. Eastern, to discuss the ... may participate in the conference call by dialing +1 888 ...
... exposure to medications, chemicals and other agentsSAN DIEGO, March ... cold medication or using certain cleaning products can now ... A new Web site ( www.ctispregnancy.org ) offering ... information about the potential risks of exposure to drugs, ...
... Dr. Holmquist Healthcare, LLC Revolutionizes the Future of Bruise ... is pleased to announce the launch of Bruise Relief(TM), ... appearance of bruising, at CVS stores and other fine ... or serum formulation and is designed to super-hydrate the ...
Cached Medicine News:Health News:Older Adults Get Drunk Faster Than Younger Drinkers 2Health News:Older Adults Get Drunk Faster Than Younger Drinkers 3Health News:Drug blocks two of world's deadliest emerging viruses 2Health News:Drug blocks two of world's deadliest emerging viruses 3Health News:SCOLR Pharma, Inc. Schedules Fourth Quarter 2008 Financial Results Conference Call for March 11, 2009 at 11:30 A.M. Eastern 2Health News:New Online Service Helps Expectant Moms 2Health News:Say Goodbye to Unsightly Bruises and Skin Discolorations with Bruise Relief(TM) 2
Inquire...
... Refrigerated incubators,Two refrigerated incubators ... life and life cycle,testing. Microprocessor ... digital temperature display. High/low audible ... contacts. Additional internal chamber safety ...
Inquire...
Inquire...
Medicine Products: